Outcomes of sofosbuvir and daclatasvir rescue therapy for decompensated hepatitis C cirrhosis

被引：0
|
作者：
Mccaughan, G. [1 ]
Thwaites, P. A. [3 ]
Roberts, S. [4 ]
Strasser, S. [1 ]
Gow, P. [3 ]
Wigg, A. [6 ]
Tallis, C. [7 ]
Jeffrey, G. [8 ]
George, J. [2 ]
Thompson, A. [5 ]
Mason, S. [1 ]
Mitchell, J. [4 ]
Angus, P. W. [3 ]
机构：
[1] Univ Sydney, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[2] Westmead Hosp, Sydney, NSW, Australia
[3] Victorian Liver Transplant Unit, Melbourne, Vic, Australia
[4] Alfred Hosp, Melbourne, Vic, Australia
[5] St Vincents Hosp, Melbourne, Vic, Australia
[6] South Australian Liver Transplant Unit, Bedford Pk, SA, Australia
[7] Queensland Liver Transplant Unit, Brisbane, Qld, Australia
[8] Western Australian Liver Transplant Unit, West Leederville, WA, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
    El Kassas, Mohamed
    Abdeen, Nermeen
    Omran, Dalia
    Alboraie, Mohamed
    Salaheldin, Mohamed
    Eltabbakh, Mohamed
    Farghaly, Rasha
    Emadeldeen, Mohammed
    Afify, Shimaa
    Sweedy, Ahmad
    Ghalwash, Ahmed
    Abbass, Amr
    Ezzat, Sameera
    Tahoon, Marwa
    ELshazly, Helmy M.
    Hamdy, Hassan
    Omar, Heba
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E877 - E882
  • [2] Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
    El Kassas, Mohamed
    Abdeen, Nermeen
    Omran, Dalia
    Alboraie, Mohamed
    Salaheldin, Mohamed
    Eltabbakh, Mohamed
    Farghaly, Rasha
    Emadeldeen, Mohammed
    Afify, Shimaa
    Sweedy, Ahmad
    Ghalwash, Ahmed
    Abbass, Amr
    Ezzat, Sameera
    Tahoon, Marwa
    ELshazly, Helmy M.
    Hamdy, Hassan
    Omar, Heba
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E877 - E882
  • [3] Outcomes of Sofosbuvir and Daclatasvir rescue therapy in decompensated Hepatitis C cirrhotics with MELD ≥ 15: final results of the Australian TOSCAR study
    McCaughan, Geoff
    Thwaites, Phoebe A.
    Roberts, Stuart K.
    Strasser, Simone I.
    Gow, Paul
    Wigg, Alan J.
    Tallis, Caroline
    Jeffrey, Gary P.
    George, Jacob
    Thompson, Alex J.
    Mitchell, Joanne
    Mason, Susan
    Morales, Brenda
    Angus, Peter W.
    [J]. HEPATOLOGY, 2016, 64 : 446A - 447A
  • [4] The TOSCAR study: sofosbuvir and daclatasvir therapy for decompensated HCV cirrhosis with MELD scores ≥ 15
    Mccaughan, G.
    Roberts, S.
    Strasser, S.
    Gow, P.
    Wigg, A.
    Tallis, C.
    Jeffrey, G.
    George, J.
    Thompson, A.
    Mason, S.
    Mitchell, J.
    Angus, P.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 89 - 89
  • [5] Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15)
    McCaughan, G. W.
    Thwaites, P. A.
    Roberts, S. K.
    Strasser, S. I.
    Mitchell, J.
    Morales, B.
    Mason, S.
    Gow, P.
    Wigg, A.
    Tallis, C.
    Jeffrey, G.
    George, J.
    Thompson, A. J.
    Parker, F. C.
    Angus, P. W.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) : 401 - 411
  • [6] Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis
    Tahata, Yuki
    Sakamori, Ryotaro
    Maesaka, Kazuki
    Doi, Akira
    Yamada, Ryoko
    Kodama, Takahiro
    Hikita, Hayato
    Miyazaki, Masanori
    Nozaki, Yasutoshi
    Kaneko, Akira
    Oshita, Masahide
    Tanaka, Satoshi
    Imanaka, Kazuho
    Hiramatsu, Naoki
    Morishita, Naoki
    Ohkawa, Kazuyoshi
    Yakushijin, Takayuki
    Sakakibara, Mitsuru
    Iio, Sadaharu
    Doi, Yoshinori
    Tatsumi, Tomohide
    Takehara, Tetsuo
    [J]. HEPATOLOGY RESEARCH, 2023, 53 (04) : 301 - 311
  • [7] Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis
    Patel, Sonalie
    Martin, Michelle T.
    Flamm, Steven L.
    [J]. LIVER INTERNATIONAL, 2021, 41 (12) : 3024 - 3027
  • [8] Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease
    Lawitz, E.
    Poordad, F.
    Gutierrez, J. A.
    Kakuda, T. N.
    Picchio, G.
    Beets, G.
    Vandevoorde, A.
    Van Remoortere, P.
    Jacquemyn, B.
    Luo, D.
    Ouwerkerk-Mahadevan, S.
    Vijgen, L.
    Van Eygen, V.
    Beumont, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2017, 24 (04) : 287 - 294
  • [9] Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C
    Quddus, Muhammad Abdul
    Zaib, Jahangir
    Munawar, Rukhsana
    Siddiq, Shazia
    Tahir, Rabia
    Kiani, Rizwan Saeed
    [J]. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2823 - 2825
  • [10] Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis
    Tmu, Naveen
    Kumar, Ashish
    Sharma, Praveen
    Singla, Vikas
    Bansal, Naresh
    Arora, Anil
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (01) : 4 - 12
12345